Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 317

Sort by

Sort Order Select

Journal Articles

Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse

Blood (2024) 144 (Supplement 1): 735.

https://doi.org/10.1182/blood-2024-203706

Published: 2024

Journal Articles

Clinical Outcomes Associated with NPM1 Mutations in Newly Diagnosed AML

Blood (2024) 144 (Supplement 1): 2853.

https://doi.org/10.1182/blood-2024-205504

Published: 2024

Journal Articles

Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease

Blood (2024) 144 (Supplement 1): 2851.

https://doi.org/10.1182/blood-2024-202429

Published: 2024

Journal Articles

Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial

Blood (2024) 144 (Supplement 1): 1765.

https://doi.org/10.1182/blood-2024-209537

Published: 2024

Journal Articles

Blood-Based Proteomic Profiling Identifies Osmr As a Novel Biomarker

Hussein A. Abbas, Bofei Wang, Jennifer Marvin-Peek, Bin Yuan, Araceli Isabella Garza, Jessica Lynn Root, Andrea Arruda, Yiwei Liu, Courtney D. DiNardo, Tapan M. Kadia, Naval Daver, Philip L Lorenzi, Koji Sasaki, Steven M. Kornblau, Mark D. Minden, Farhad Ravandi, Hagop M. Kantarjian, Patrick K. Reville

Blood (2024) 144 (Supplement 1): 2912.

https://doi.org/10.1182/blood-2024-201725

Published: 2024

Journal Articles

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome

Blood (2024) 144 (Supplement 1): 3212.

https://doi.org/10.1182/blood-2024-205186

Published: 2024

Journal Articles

Combination Therapy with Nelarabine, Peg-Asparaginase and Venetoclax for Adults Patients with Relapsed/Refractory T-Cell ALL

Niranjan Shiwaji Khaire, Elias Jabbour, Tapan M. Kadia, Nicholas J. Short, Gautam Borthakur, Naveen Pemmaraju, Naval Daver, Partow Kebriaei, Shilpa Paul, Vishrut Shah, Rebecca Garris, Koji Sasaki, Farhad Ravandi, Nitin Jain

Blood (2024) 144 (Supplement 1): 4207.

https://doi.org/10.1182/blood-2024-206697

Published: 2024

Journal Articles

ASXL1 Mutations in AML Are Associated with a Distinct Epigenetic State Which Highlights Vulnerabilities to Specific Epigenetic-Targeted Agents

Christopher Peter Mill, Warren C. Fiskus, Christine Birdwell, John A. Davis, Kaberi Das, Hanxi Hou, Surbhi Sharma, Koji Sasaki, Sanam Loghavi, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo, Lu Wang, Kapil N. Bhalla

Blood (2024) 144 (Supplement 1): 1349.

https://doi.org/10.1182/blood-2024-204117

Published: 2024

Journal Articles

Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI)

Ehab L. Atallah, Moshe Y. Levy, Paul B. Koller, Koji Sasaki, Srinivas K Tantravahi, David Andorsky, Celesteann T Bremer, Joshua F Zeidner, Marlise R. Luskin, Reinhold Munker, Daisy Yang, Dramane Laine, John Sabo, Ennan Gu, Michael J. Mauro, Jorge E. Cortes

Blood (2024) 144 (Supplement 1): 479.

https://doi.org/10.1182/blood-2024-200717

Published: 2024

Journal Articles

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update

Blood (2024) 144 (Supplement 1): 219.

https://doi.org/10.1182/blood-2024-200393

Published: 2024

Journal Articles

Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML

Blood (2024) 144 (Supplement 1): 216.

https://doi.org/10.1182/blood-2024-204375

Published: 2024

Journal Articles

Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 ( SF3B1 del5q ): Outcomes and Response to Treatment

Blood (2024) 144 (Supplement 1): 1845.

https://doi.org/10.1182/blood-2024-207474

Published: 2024

Journal Articles

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10 -4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Blood (2024) 144 (Supplement 1): 1855.

https://doi.org/10.1182/blood-2024-211110

Published: 2024

Journal Articles

Distinct Impact of Platinum Chemotherapies on the Fitness and Genome of Hematopoietic Stem Cells and the Risk of Therapy-Related Myeloid Neoplasms

Blood (2024) 144 (Supplement 1): 1816.

https://doi.org/10.1182/blood-2024-212052

Published: 2024

Journal Articles

A Retrospective Analysis of Ponatinib-Based Therapy in Patients with Myeloid Blast Phase Chronic Myeloid Leukemia: Responses Rates, Outcomes and Patterns of Relapse

Omer Karrar, Elias Jabbour, Jayastu Senapati, Fadi G. Haddad, Ghayas C. Issa, Koji Sasaki, Hussein A. Abbas, Sara Emogene Dellasala, Farhad Ravandi, Hagop M. Kantarjian, Nicholas J. Short

Blood (2024) 144 (Supplement 1): 3156.

https://doi.org/10.1182/blood-2024-206644

Published: 2024

Journal Articles

Outcomes of Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Having Myeloid Type Mutations Treated with Inotuzumab/Blinatumomab Containing Frontline Regimens

Jayastu Senapati, Hagop M. Kantarjian, Clark Robinson, Koichi Takahashi, Nitin Jain, Fadi G. Haddad, Courtney D. DiNardo, Sanam Loghavi, Guilin Tang, Guillermo Montalban-Bravo, Tapan M. Kadia, Naval Daver, Koji Sasaki, Zena Komrokji, Rebecca Garris, Guillermo Garcia-Manero, Farhad Ravandi, Nicholas J. Short, Elias Jabbour

Blood (2024) 144 (Supplement 1): 1461.

https://doi.org/10.1182/blood-2024-204181

Published: 2024

Journal Articles

Identifying ‘Druggable’ Targets and Preclinically Overcoming Non-Genetic/Adaptive Resistance to Menin Inhibitors in AML with MLL1r or mtNPM1

Warren C. Fiskus, Christopher Peter Mill, Jessica Piel, Mike Collins, Murphy Hentemann, Christine Birdwell, Kaberi Das, John A. Davis, Hanxi Hou, Surbhi Sharma, Koji Sasaki, Sanam Loghavi, Branko Cuglievan, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo, Kapil N. Bhalla

Blood (2024) 144 (Supplement 1): 1373.

https://doi.org/10.1182/blood-2024-206374

Published: 2024

Journal Articles

Characteristics of Myelodysplastic Syndromes with Idiopathic Pulmonary Fibrosis

Ines Zugasti, Samuel Urrutia, Eduardo Edelman Saul, Georgina Daher-Reyes, Mohammed Asim Amjad, Jia Wu, Koji Sasaki, Ajay Sheshadri, Guillermo Garcia-Manero

Blood (2024) 144 (Supplement 1): 4587.

https://doi.org/10.1182/blood-2024-207293

Published: 2024

Journal Articles

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis

Blood (2024) 144 (Supplement 1): 4584.

https://doi.org/10.1182/blood-2024-210646

Published: 2024

Journal Articles

Neighborhood Disadvantage Impacts Outcomes in Patients with Myelodysplastic Syndromes across Different Racial Backgrounds

Mahesh Swaminathan, Daniel Aaron Fox, Kelly S. Chien, Guillermo Montalban-Bravo, Danielle Hammond, Alexandre Bazinet, Sherry Pierce, Hyunsoo Hwang, Xuelin Huang, Koji Sasaki, Tapan M. Kadia, Koichi Takahashi, Courtney D. DiNardo, Elias Jabbour, Naval Daver, Hagop M. Kantarjian, Guillermo Garcia-Manero

Blood (2024) 144 (Supplement 1): 2438.

https://doi.org/10.1182/blood-2024-200390

Published: 2024

NARROW

Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse

Clinical Outcomes Associated with NPM1 Mutations in Newly Diagnosed AML

Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease

Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial

Blood-Based Proteomic Profiling Identifies Osmr As a Novel Biomarker

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome

Combination Therapy with Nelarabine, Peg-Asparaginase and Venetoclax for Adults Patients with Relapsed/Refractory T-Cell ALL

ASXL1 Mutations in AML Are Associated with a Distinct Epigenetic State Which Highlights Vulnerabilities to Specific Epigenetic-Targeted Agents

Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI)

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update

Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML

Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 ( SF3B1 del5q ): Outcomes and Response to Treatment

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10 -4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Distinct Impact of Platinum Chemotherapies on the Fitness and Genome of Hematopoietic Stem Cells and the Risk of Therapy-Related Myeloid Neoplasms

A Retrospective Analysis of Ponatinib-Based Therapy in Patients with Myeloid Blast Phase Chronic Myeloid Leukemia: Responses Rates, Outcomes and Patterns of Relapse

Outcomes of Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Having Myeloid Type Mutations Treated with Inotuzumab/Blinatumomab Containing Frontline Regimens

Identifying ‘Druggable’ Targets and Preclinically Overcoming Non-Genetic/Adaptive Resistance to Menin Inhibitors in AML with MLL1r or mtNPM1

Characteristics of Myelodysplastic Syndromes with Idiopathic Pulmonary Fibrosis

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis

Neighborhood Disadvantage Impacts Outcomes in Patients with Myelodysplastic Syndromes across Different Racial Backgrounds

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only